Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
Biotech ETFs receive a dose of gains on new variant concern
Investors rushed to Biotech and Pharma shares, betting on current vaccine efficacy and renewed demand for doses to fend off the virus.
By Rony Abboud
0
- Technology
- Chemicals
Advertisement
While most shares flashed red last week, Biotech and Pharma shares rose on new variant concerns. The new variant called "Omicron" was first spotted in South African and made its way across continents with cases in the U.K., Hong Kong, Australia, and Denmark among others.
Investors rushed to Biotech and Pharma shares, betting on current vaccine efficacy and renewed demand for doses to fend off the virus. The rush lifted shares of Pfizer, Moderna, BioNtech by +6.11%, +20.57% and +14.19% on Friday, making the Biotech Industry the top performer in the S&P 500 last week with a combined gain of +3.84%.
ETF Data Built for Precision
Trackinsight delivers reliable and comprehensive coverage on 14,000+ ETFs
In the American ETF space, VanEck Biotech ETF and iShares Biotechnology ETF gained +2.2% and 0.98% on Friday 26th of November. In Europe, Invesco NASDAQ Biotech UCITS ETF and iShares Nasdaq US Biotechnology UCITS ETF opened higher on Monday and currently trading over +1% higher than last Friday's closing prices (11:57 AM, GMT +1).
Find and compare over 7,000 ETFs with our free tools: 
Interested in seeing lists of top performing ETFs? Check out our new Investing Guides:
More articles
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
